CAMBRIDGE, Mass., September 15, 2023 – BWB Awards, a part of Biotech Week Boston, has named Senda Biosciences a finalist in the “Biotech Innovation” category. The Biotech Innovation award recognizes a company or organization that has conceived a new or advancing biopharmaceutical product, manufacturing process or ground-breaking technology that yielded significant results.
Senda is the first and only company to use nature’s codes to program information molecules, such as mRNA, both within and to target cells. Leveraging a deep understanding of how natural nanoparticles facilitate the transport of biomolecules into human cells, Senda is developing SendRNAs™ – a new class of fully programmable mRNA medicines using proprietary Senda nanoparticles that are unlocking new levels of speed, breadth, and productivity to develop therapies for a wide range of diseases.
“It’s an honor to be recognized for our groundbreaking platform,” said Guillaume Pfefer, Ph.D., CEO of Senda Biosciences and CEO-Partner of Flagship Pioneering. “At Senda, we are pioneering programmable medicines that we believe will create a paradigm shift in how we treat disease, with the potential to make a tremendous impact on the lives of patients.”
Since 2018 the BWB Awards have recognized top individuals, companies, and organizations within the life sciences community and brought together the brightest minds and biggest names, establishing Boston as the vibrant hub of the biotech world.
The award ceremony will take place on September 18. For more information, visit https://informaconnect.com/bwb-awards/.
About Senda Biosciences
Senda Biosciences, Inc. is committed to bringing life-changing treatments to patients by harnessing millennia of evolution to program human cells both within and to the cell. Senda’s proprietary platform is the first to leverage a universal chemical addressing code of natural nanoparticles that enable cross-kingdom intercellular communication. This platform unlocks comprehensive programming of medicines for the first time, allowing Senda to develop a new class of SendRNA™ medicines focused initially on powering new frontiers in immunology mRNA-based therapies, with future applications employing other information molecules, including siRNA, gene editors, proteins, and peptides. Headquartered in Cambridge, Massachusetts, Senda was founded by Flagship Pioneering.
Contact: Georgina Vincent, Head of Communications, email@example.com